These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23428587)

  • 21. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
    Hatano M; Yao A; Kinugawa K; Hirata Y; Nagai R
    Int Heart J; 2011; 52(4):233-9. PubMed ID: 21828950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Liu H; Liu ZY; Guan Q
    Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):608-13. PubMed ID: 17670742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.
    Kuang T; Wang J; Pang B; Huang X; Burg ED; Yuan JX; Wang C
    Pulm Pharmacol Ther; 2010 Oct; 23(5):456-64. PubMed ID: 20188205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.
    Gosal K; Dunlop K; Dhaliwal R; Ivanovska J; Kantores C; Desjardins JF; Connelly KA; McNamara PJ; Jain A; Jankov RP
    Am J Respir Cell Mol Biol; 2015 Jun; 52(6):717-27. PubMed ID: 25337652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
    Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
    J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle.
    Borgdorff MA; Bartelds B; Dickinson MG; Boersma B; Weij M; Zandvoort A; Silljé HH; Steendijk P; de Vroomen M; Berger RM
    Eur J Heart Fail; 2012 Sep; 14(9):1067-74. PubMed ID: 22730335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.
    Alencar AK; Carvalho FI; Silva AM; Martinez ST; Calasans-Maia JA; Fraga CM; Barreiro EJ; Zapata-Sudo G; Sudo RT
    PLoS One; 2018; 13(4):e0195047. PubMed ID: 29677206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
    Tawara S; Fukumoto Y; Shimokawa H
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
    Sawamura F; Kato M; Fujita K; Nakazawa T; Beardsworth A
    J Pharmacol Sci; 2009 Nov; 111(3):235-43. PubMed ID: 19881228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension.
    Karpuz D; Hallioglu O; Buyukakilli B; Gurgul S; Balli E; Ozeren M; Tasdelen B
    Bratisl Lek Listy; 2017; 118(9):544-551. PubMed ID: 29061062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling.
    Yen CH; Leu S; Lin YC; Kao YH; Chang LT; Chua S; Fu M; Wu CJ; Sun CK; Yip HK
    J Cardiovasc Pharmacol; 2010 Jun; 55(6):574-84. PubMed ID: 20224427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
    Li FH; Xia W; Li AW; Zhao CF; Sun RP
    Chin Med J (Engl); 2007 Jan; 120(1):22-9. PubMed ID: 17254483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
    Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
    Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
    Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
    Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
    Schermuly RT; Kreisselmeier KP; Ghofrani HA; Yilmaz H; Butrous G; Ermert L; Ermert M; Weissmann N; Rose F; Guenther A; Walmrath D; Seeger W; Grimminger F
    Am J Respir Crit Care Med; 2004 Jan; 169(1):39-45. PubMed ID: 12958054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
    Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
    Yigitaslan S; Sirmagul B
    Clin Exp Hypertens; 2012; 34(3):222-9. PubMed ID: 22468718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.
    Humpl T; Reyes JT; Erickson S; Armano R; Holtby H; Adatia I
    Cardiol Young; 2011 Apr; 21(2):187-93. PubMed ID: 21138617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.